News | July 23, 2024
Solara Active Pharma Sciences reports Q1 FY25 consolidated loss at Rs. 13.46 Cr
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension
RPG Life Sciences has reported total income of Rs. 167.79 crores during the period ended June 30, 2024
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
The pooled prevalence of GERD in the Indian population is 15.6 %
Vimta Labs has reported total income of Rs. 82.44 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
